Tirosint and Bupropion Interaction: What Patients and Prescribers Need to Know

Tirosint is a brand-name liquid-filled gel capsule formulation of levothyroxine sodium, a synthetic thyroid hormone (T4) used for hypothyroidism and for TSH suppression after thyroid cancer treatment. Bupropion (brand names Wellbutrin, Wellbutrin SR/XL, Zyban) is a norepinephrine-dopamine reuptake inhibitor (NDRI) approved for major depressive disorder and smoking cessation. The two are frequently prescribed together, and this article covers what is known about combining them, what is plausible but unproven, and what monitoring a clinician or pharmacist should confirm.

This article does not cover interactions between bupropion and other levothyroxine formulations, and it is not a substitute for an individualized medication review with a prescriber or pharmacist.

Direct answer

Tirosint and bupropion do not have a documented pharmacokinetic interaction: bupropion does not measurably change how levothyroxine is absorbed or cleared, because levothyroxine is metabolized through deiodination and conjugation rather than cytochrome P450 pathways. The concern is pharmacodynamic. Both drugs increase adrenergic (sympathetic) tone through separate mechanisms, so poorly controlled thyroid hormone levels combined with bupropion's noradrenergic activity can produce an amplified cardiovascular response, including faster heart rate and higher blood pressure. Current FDA labeling for both drug classes and standard drug-interaction references classify this as a moderate-severity interaction that calls for monitoring rather than avoidance, and the practical safeguard is confirming that thyroid function is in the intended range before and after starting either drug.

What is established, what is plausible, and what is not established

Established, from FDA labeling and pharmacology:

• Levothyroxine is not a cytochrome P450 substrate, so bupropion's CYP2D6 inhibition does not directly change levothyroxine levels.
• The levothyroxine label warns that thyroid hormone can enhance the effects of sympathomimetic-type drugs and increase cardiovascular risk when combined with agents that raise catecholamine activity (see FDA label below).
• The bupropion label warns of dose-dependent seizure risk and advises caution when combining bupropion with other drugs or conditions that alter dopaminergic or noradrenergic activity (see FDA label below).
• Bupropion inhibits CYP2D6, a pathway used by several other common drugs, including some beta-blockers and tamoxifen. This is a real and independently documented pharmacologic effect, separate from the thyroid interaction.

Plausible but not established in a controlled trial of this specific combination:

• That over-replacement with Tirosint combined with bupropion produces a larger cardiovascular effect than either drug alone at therapeutic levels. This follows from receptor pharmacology (thyroid hormone upregulates cardiac beta-1 receptors; bupropion raises synaptic norepinephrine) but has not been quantified in a dedicated clinical trial of levothyroxine plus bupropion.
• That an over-replaced thyroid state meaningfully adds to bupropion's seizure risk. Hyperthyroidism is understood to lower seizure threshold and bupropion's risk is dose-dependent, but the combined, additive magnitude in a single patient has not been measured prospectively.
• That switching from tablet levothyroxine to Tirosint changes free T4 enough to unmask a previously silent interaction with bupropion. This is a reasonable inference from known absorption differences between formulations, not a finding from a trial that tested this specific switch alongside bupropion.

Not established:

• Any specific numeric estimate of how much bupropion increases cardiovascular risk in a levothyroxine-treated patient, or vice versa. Precise incidence figures for this combined scenario were not located in the primary literature reviewed for this article and should not be treated as verified until confirmed against current product labeling or a controlled study.
• That the two drugs need to be separated by time of day. Because there is no absorption-level interaction, there is no established timing requirement between them.

Why the combination is pharmacologically plausible

Levothyroxine is converted peripherally to triiodothyronine (T3), which increases beta-1 adrenergic receptor expression in heart tissue. At a normal, on-target thyroid state, this has little clinical consequence. If free T4 or T3 rises above the intended range, the heart becomes more responsive to circulating norepinephrine.

Bupropion blocks reuptake of norepinephrine and dopamine, raising synaptic norepinephrine availability. In a patient whose cardiac adrenergic receptors are already upregulated by excess thyroid hormone, that additional norepinephrine has more receptors to act on, which is the plausible mechanism behind reports of tachycardia, elevated blood pressure, and occasional palpitations when the two drugs are combined in an under-monitored patient.

This mechanism does not require levothyroxine dose changes if TSH and free T4 are already at target. It is relevant specifically when thyroid hormone levels drift high, whether from a dose that is too aggressive, a formulation switch that improves absorption, or a missed recheck after starting either drug.

Third-drug interactions through CYP2D6

Bupropion is a clinically significant inhibitor of CYP2D6. Levothyroxine itself is not affected, but other drugs commonly used by patients on thyroid hormone replacement can be:

• Metoprolol and other CYP2D6-dependent beta-blockers may reach higher plasma levels when bupropion is added, raising the risk of bradycardia. In a patient on Tirosint, bupropion, and a beta-blocker, new bradycardia should prompt review of the beta-blocker level or dose, not an assumption that the thyroid dose is the cause.
• Tamoxifen requires CYP2D6 conversion to its active metabolite. Co-administration with a strong CYP2D6 inhibitor such as bupropion is a recognized concern for reduced tamoxifen effectiveness and is typically addressed by using an alternative antidepressant in patients on tamoxifen where possible.
• Codeine requires CYP2D6 activation to morphine; bupropion can blunt codeine's analgesic effect.

These interactions exist independent of the thyroid hormone question and should be checked against the patient's full medication list rather than assumed away because the levothyroxine interaction is pharmacodynamic.

Monitoring approach

• Obtain baseline TSH and free T4 before adding bupropion to an established Tirosint regimen, or before adding Tirosint to an established bupropion regimen.
• Recheck thyroid function roughly 6 to 8 weeks after either drug is started or changed, which is a standard interval for a new thyroid hormone steady state to be reflected in labs; this timing is longstanding endocrine practice rather than a bupropion-specific rule.
• Check resting heart rate and blood pressure at visits during the first few months of combined therapy. A sustained resting heart rate that trends upward, even with a previously normal TSH, is a reason to recheck free T4, since TSH can lag behind a rising free T4.
• Confirm TSH is not markedly suppressed before increasing bupropion beyond an initial low dose, particularly in patients whose seizure risk factors (history of seizure, eating disorder, heavy alcohol use, abrupt benzodiazepine discontinuation) are already elevated.
• Ask specifically about St. John's Wort and other unlisted supplements; St. John's Wort induces metabolic enzymes and is a recognized reason for reduced antidepressant effect, independent of the thyroid interaction, though the exact magnitude of that reduction should be confirmed with a pharmacist rather than assumed.

Dose adjustment principles

Tirosint dose changes should be driven by TSH and clinical status, not by the presence of bupropion alone. If TSH is at target and the patient has no new symptoms, adding bupropion is not, by itself, a reason to change the thyroid hormone dose.

Reasons to reassess the Tirosint dose after starting bupropion include a TSH that falls below target at the follow-up check, new or worsening tachycardia or atrial arrhythmia, new tremor, or symptoms of heat intolerance and unintended weight loss.

Bupropion dosing should follow its own label guidance, generally starting low and titrating gradually. If new tremor, agitation, or palpitations appear after a bupropion dose increase, checking TSH and free T4 before further escalation helps distinguish a thyroid-driven cause from a bupropion side effect, since the symptom overlap between the two is substantial.

Special populations

Cardiovascular disease. Patients with existing coronary artery disease or heart failure are generally managed toward a TSH in the higher end of the normal range rather than a tightly suppressed one, and cardiology or endocrinology input is reasonable before starting bupropion at a moderate-to-higher dose in this group.

Thyroid cancer with intentional TSH suppression. Patients on Tirosint doses intended to suppress TSH below the normal range for thyroid cancer management already carry a degree of intentional over-replacement. Adding bupropion in this group deserves closer cardiovascular attention and communication between the oncology and prescribing teams, since the baseline adrenergic sensitization is already present by design.

Pregnancy. Levothyroxine dose requirements commonly increase during pregnancy and require closer TSH monitoring; specific first-trimester dose-increase percentages vary by patient and should be confirmed with the treating endocrinologist rather than applied as a fixed rule. Bupropion's reproductive safety data are limited, and any association with congenital defects has been debated across studies; a pregnant patient and prescriber should weigh the indication for bupropion against uncertainty in the safety data and consider alternatives where appropriate.

Older adults. Thyroid hormone's cardiovascular effects are generally more pronounced with age, and clinical trial evidence in older adults with mild (subclinical) hypothyyroidism has not shown a consistent symptom benefit from treatment at borderline TSH thresholds. This supports a conservative approach to both Tirosint titration and bupropion initiation in older patients, without over-reading a single trial's findings onto every older adult.

Symptoms that warrant contacting a prescriber, and symptoms that need urgent care

Contact the prescribing clinician without waiting for a scheduled visit for new or worsening palpitations, tremor, unexplained sweating, new anxiety or insomnia that begins after a dose change, or unintended weight loss.

Seek emergency care for a seizure, chest pain, fainting, a very rapid or irregular heartbeat that does not resolve with rest, or signs of a hypertensive emergency (severe headache with very high blood pressure, vision changes, confusion). These symptoms should not be managed by adjusting either medication at home.

Timing and administration

Tirosint is typically taken on an empty stomach, 30 to 60 minutes before the first meal of the day, consistent with standard levothyroxine administration practice. Bupropion extended-release can generally be taken with or without food. There is no established pharmacokinetic reason to separate the two by time of day, since the interaction between them is not an absorption-level interaction. Calcium, iron, and high-fiber supplements can still reduce levothyroxine absorption and should be separated from Tirosint dosing by several hours, per standard levothyroxine counseling.

Evidence-status interaction assessment

Refer to this table to distinguish between established levothyroxine-tirosint interactions that can be stated with certainty and those interactions requiring individual patient verification.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Tirosint (levothyroxine sodium) capsules prescribing information.
2. U.S. Food and Drug Administration. Bupropion hydrochloride extended-release tablets prescribing information.

A dedicated PubMed search for a trial or observational study specifically evaluating combined Tirosint (or levothyroxine) and bupropion use did not return a directly matching primary source at the time this draft was prepared. Statements above that reference general pharmacology of CYP2D6 interactions, thyroid hormone cardiovascular effects, or trial evidence in older adults with subclinical hypothyroidism should be treated as requiring verification against the primary literature before being presented to a patient as a numerically precise finding. This flag should be resolved during medical review before publication.